SynthesisBiomolecules & biomedicine2026
Neutrophil-to-lymphocyte ratio as a prognostic biomarker in lung cancer patients treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.
Synthesis in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) continues to be a leading cause of cancer-related mortality, highlighting the need for reliable and accessible biomarkers to identify patients at higher risk of poor outcomes during immunotherapy. This systematic review and meta-analysis aimed to evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with LC receiving programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. Comprehensive searches were conducted in the Cochrane Library, Web of Science, Embase, and PubMed up to February 13, 2025, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS), and pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated employing random-effects models. A total of 49 studies encompassing 7,897 patients were analyzed. Elevated NLR was significantly associated with shorter overall survival (OS) (HR = 1.92, 95% CI: 1.70-2.17) and progression-free survival (PFS) (HR = 1.66, 95% CI: 1.48-1.87). These associations remained consistent across most subgroups and sensitivity analyses, including those focused on non-small cell lung cancer (NSCLC) patients with pretreatment NLR measurements. However, it is important to consider heterogeneity and potential publication bias regarding PFS when interpreting these findings. Elevated NLR is indicative of poorer survival outcomes in patients with LC treated with PD-1/PD-L1 inhibitors and may function as a practical prognostic biomarker. Nonetheless, prospective studies with standardized cutoff values are necessary prior to routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.